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Abstract
Objectives To establish whether long-term use of melatonin
influences pubertal development, sleep quality and mental
health development in children as compared with the
normal Dutch population of the same age.
Methods This follow-up research study was conducted in
children included in a previous melatonin dose-finding trial.
Outcomes were measured using questionnaires (Strength
and Difficulties Questionnaire (SDQ), Children's Sleep
Habits Questionnaire (CSHQ) and Tanner Stages) adopted
for Dutch children. Mean duration of therapy, persistence of
effect, adverse events and (other) reasons leading to
cessation of therapy were additional objectives of this
study.
Results Mean years of usage (n=51) was 3.1 years (min
1.0 year, max 4.6 years), mean dose 2.69 mg (min 0.3 mg,
max 10 mg). Mean SDQ score, mean CSHQ score and
Tanner Stages standard deviation scores did not differ in a
statistically significant way from published scores of the
general Dutch population of the same age and sex.
Conclusions This follow-up study demonstrates that mela-
tonin treatment in children can be sustained over a long
period of time without substantial deviation of the
development of children with respect to sleep quality,
puberty development and mental health scores, as com-
pared with the general Dutch population.
Keywords Melatonin treatment.Puberty.
Long-term effects.CSHQ.SDQ.Tanner
Introduction
The prevalence of chronic sleep onset insomnia (CSOI) is
approximately 10% among the non-disabled school-aged
population (Blader et al. 1997). CSOI is the inability to
fall asleep at the desired sleep time. A stable sleep
schedule that is substantially later than the conventional
or desired time is one of the main symptoms of delayed
sleep phase disorder (DSPD) (Sack et al. 2007). CSOI,
combined with the finding of (an age relative) late dim
light melatonin onset (DLMO), is suggestive for DSPD.
Late melatonin onset in children between 6 and 12 years
old is defined as a DLMO later than the mean DLMO in
children without CSOI, being 19:45±60 min in children of
8.2±2.1 years (Smits et al. 2003).
In the Netherlands, melatonin is increasingly used for the
treatment of children with idiopathic CSOI and late
melatonin onset. In the second half of 2008, melatonin
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DOI 10.1007/s00213-011-2202-ycapsules took the fifth rank of extemporaneous mixtures
compounded in Dutch pharmacies (Anonymous 2009).
A recent meta-analysis showed the short-term efficacy
and safety of melatonin in adults as well as in children with
a mean reported DLMO between 20:37 and 21:06 (van
Geijlswijk et al. 2010a). Also in children with attention
deficit hyperactivity disorder (van der Heijden et al. 2007;
Weiss and Salpekar 2010) or autistic spectrum disorder
(Cortesi et al. 2010), melatonin effectively improved
quality of sleep.
However, treatment of children with melatonin has been
controversial, because of its effects on reproduction in
animals (Arendt 1997; Szeinberg et al. 2006).
Schertbarth et al. concluded that the normal variation in
melatonin levels resulted in different results of gonadotro-
phic effect and reproduction, depending on the animal
species involved. Melatonin is solely the mediator for the
environmental cue that activates the seasonal breeder
organism in a species appropriate way to the seasonal
changes (Scherbarth and Steinlechner 2010).
Even though humans are no seasonal breeders, there is
still concern that enduring high nocturnal levels due to
exogenous melatonin uptake might postpone puberty onset
(Srinivasan et al. 2009).
Case reports of precocious puberty (Waldhauser et al.
1991) and delayed puberty development associated with a
disturbed melatonin rhythm (Verhoeven and Massa 2005)
have led to different hypotheses about puberty and lowered
nocturnal melatonin levels (Waldhauser et al. 1991;
Debruyne 2006; Srinivasan et al. 2009; Silman 2010). The
lower nocturnal levels of melatonin in children after onset
of puberty and adults might stem from growth (Silman
2010). However, in children with precocity, also lower
nocturnal melatonin levels are found in comparison with
preadolescent children of the same age and stature
(Waldhauser et al. 1991). This suggests that lower levels
of melatonin are not a result of a larger volume of
distribution due to growth. Moreover, after suppression of
the pituitary–gonadal axis, resulting in a normalized
gonadotropin and sex steroid levels, these lower melatonin
levels do not normalize to age-related preadolescent levels.
This implies melatonin levels are not determined by
hormonal status.
Long-term data on efficacy and safety are scarce and
especially with respect to pubertal development needed. A
recently published long-term study (Hoebert et al. 2009)
suggested that long-term use of melatonin is safe. However,
these authors did not study the influence on pubertal
development.
The objective of this study was to evaluate the long-term
efficacy and the long-term safety of melatonin therapy in
pre-pubertal children. This is, to our knowledge, the first
study evaluating pubertal development in children using
melatonin for a long period of time in pre-puberty as
compared with pubertal development in the general Dutch
population (controls).
Methods and materials
Study design
For this follow-up study, all participants of the Meldos trial,
a melatonin dose-finding investigation in children with
CSOI were invited (van Geijlswijk et al. 2010b). The study
consisted of a written interview with inventory questions
about demographic data and melatonin use and three
international questionnaires about sleep habits, mental
health and pubertal development, adapted to the population
of Dutch children. The children, having used melatonin for
6 months or longer, were asked to complete the full
questionnaire. The Meldos protocol was approved by the
institutional review board, as a mono-centre trial by the
Central Committee on Research Involving Human Subjects,
and registered in the International Standard Randomized
Controlled Trial Number Register (ISRCTN20033346).
The protocol included the possibility to assess health
several years after finishing the placebo-controlled part of
the study.
Participants
All children that participated in the Meldos trial between
May 2004 and February 2007 (van Geijlswijk et al.
2010b) were eligible to participate in this follow-up
study. After finishing the Meldos trial, the participants
were prescribed with melatonin; the dose was determined
by the subjective results of the last trial week. In the
previous Meldos trial, eligible participants were children
aged between 6 and 12 years who were in good general
health, otherwise suffering from sleep onset insomnia
more than four nights a week for more than 1 year,
based on parental reports. Sleep onset insomnia was
defined as sleep onset later than 8:30P.M.i nc h i l d r e na g e d
6 years and for older children, 15 min later per year until
age 12 (10:00 P.M.). Furthermore, the latency between
lights-off time and sleep onset (sleep onset latency) had to
be more than 30 min on average. Sleep hygiene inter-
ventions did not result in better sleep. Exclusion criteria
were CSOI due to psychiatric or pedagogic problems,
known intellectual disability, pervasive developmental
disorder, chronic pain, known disturbed hepatic or renal
function, epilepsy, prior use of melatonin, and use of
stimulants, neuroleptics, benzodiazepines, clonidine, anti-
depressants, hypnotics, or beta-blockers within 4 weeks
before enrolment.
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children who completed the placebo-controlled part of the
Meldos trial.
Outcome measures
The questionnaire consisted of four distinct parts.
1. Demographic data and melatonin use.
Part I were 24 multiple choice, open and scaled
questions about continuance of melatonin usage, the
way melatonin prescription was obtained, the applied
dose(s), therapy compliance, drug-holidays, other med-
ication, length and weight, school, sports, reading
activities, gaming and watching TV, occurrence and
severity of headache.
2. Mental health
In part II, 25 questions about mental health, to assess
social development were asked. Mental health was
assessed by means of the self-administered Dutch version
of the Strengths and Difficulties Questionnaire (SDQ) for
adolescents and children. The SDQ is a questionnaire that
is suitable as an index of therapy outcome (Garralda et al.
2000; Goodman 2001; Muris et al. 2003).
It includes 25 symptom items and measures both
negative and positive behavioural and emotional attrib-
utes of the child or adolescent. There are five sub-scales:
emotional symptoms, conduct problems, hyperactivity–
inattention, peer relationship problems and pro-social
behaviour. Every item has three categories: ‘not true’ (0),
‘somewhat true’ (1) or ‘certainly true’ (2). The scores
were summed for each scale. A total difficulties score
w a sc a l c u l a t e db ys u m m i n gt h es c o r e so fa l lt h ei t e m s ,
except those of the pro-social behaviour scale. This
Dutch version is validated as a parents questionnaire in
the Dutch population (Muris et al. 2003)( M u r i se ta l .
2004), and it is also used as a self-administered version
in 13 and 14-year-old children (Havas et al. 2010). The
SDQ in this study addressed the parents and children,
irrespective of age.
3. Sleep habits
Part III consisted of the Children's Sleep Habits
Questionnaire (CSHQ), which is a retrospective, 45-
item parent questionnaire that has been used in a
number of studies to examine sleep behaviour in young
children. The CSHQ includes sleep complaints in this
age group: bedtime behaviour and sleep onset; sleep
duration; anxiety around sleep; behaviour occurring
during sleep and night wakings; sleep-disordered
breathing; parasomnias; and morning waking/daytime
sleepiness. Parents are asked to recall sleep behaviours
occurring over a ‘typical’ recent week. Items are rated
on a three-point scale: ‘usually’ if the sleep behaviour
occurred five to seven times/week; ‘sometimes’ for two
to four times/week; and ‘rarely’ for zero to one time/
week (Owens et al. 2000). The Dutch version was
recently validated in the Dutch population (Waumans et
al. 2010). The tool to objectify sleep in the Meldos
study was dim light melatonin onset (DLMO) and
Sleep Onset and Sleep Onset Latency, obtained by
actigraphy. Additionally, sleep hygiene measures in
Meldos were evaluated by means of a questionnaire
based on the Sleep Disturbance Scale of Children
(SDCS) (Bruni et al. 1996). Since these parameters
change with age, especially in puberty, repeating these
measurements for this study seemed of less value than
comparing the outcomes of this questionnaire to
outcomes in controls.
4. Pubertal development
Pubertal development was assessed by three Tanner
score questions and one additional question for girls
(mothers age at menarche) and two additional questions
for boys (oigarche age [the age at first ejaculation
(Laron et al. 1980; Carlier and Steeno 1985)] of him
and his father).
TheTannerscoresconsistofthreescoresforboysandthree
for girls, describing size of genitals, testicles and growth of
pubic hair in boys, and breasts, pubic hair and menarche in
girls (Marshall and Tanner 1969; Marshall and Tanner 1970).
The Tanner scores were self-reported, based on photographs
and sketches of testicle volumes added to the questionnaire
(Vlaamse Groeicurven 2004 [Flemish Growth Charts]: http://
www.vub.ac.be/groeicurven/pubemodel.html). Results in our
population were compared with the general Dutch popula-
tion (Mul et al. 2001)t oa s s e s sp u b e r t a ld e v e l o p m e n t .
Timing of pubertal development is influenced by genetic
factors. Comparison of pubertal timing between generations
is difficult because of the absence of a distinct criterion
apart from menarche in girls (Carskadon and Acebo 1993;
Sedlmeyer et al. 2002; Wehkalampi et al. 2008). The age of
oigarche was added as a menarche equivalent for boys for
its distinct value, if attainable. The parents' ages at
menarche and oigarche were retrieved as indicators for
genetic predisposition for early or late puberty onset.
A successful pilot of the questionnaire was done in five
children.
Data analysis
Primary outcomes are SDQ score, CSHQ score and Tanner
scores of children under melatonin treatment for more than
6 months. Secondary outcomes are percentage of persistent
use of melatonin in this group of children, mean effective
dose, reported adverse events, menarche/oigarche related to
parental menarche/oigarche.
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sample t test was applied to compare scores obtained in
(subgroups of) this population with previously published
scores of the general Dutch population of the same age and/
or sex (controls). Additionally, the CSHQ score was
compared with the score in a subpopulation identified as
without sleeping problems, and with the score in a
subpopulation with sleeping problems.
Tanner scores were analyzed using the web application
(http://vps.stefvanbuuren.nl/puberty) (van Buuren and
Ooms 2009). This tool calculates standard deviation scores
(SDS) of individual observations of Tanner scores, and
additionally plots those scores in a stage line diagram. The
traditional way to evaluate an individual's score to a
population is the application of a nomogram, which
calculates the relative position of the individual as
compared with his/hers age-peers. This is suitable for
continuous parameters like length or weight, the standard
deviation of the mean determining the relative position
between 0 and 100, p0 meaning that 0% of the general
population is smaller/weighing less, p100 that 0% of the
general population is taller/weighing more. But it is not
very convenient for processes that occur in a limited period
of time, like breast growth and are characterized by discrete
measures (stages) instead of a continued parameter. The
determination of the deviation of a distinct stage at a
specified age in relationship to the distribution (expressed
in SDS) of this stage over ages in controls (data of 1997
(Mul et al. 2001)) moderates the evaluation of puberty
development in a more continuous way. The stage line
diagram is created by modelling the probabilities of
successive category transitions in the reference data
(general population) as functions that are smooth in age.
Then, the mid-p value for each category is calculated and
transformed into the Z scale by a probit transformation (van
Buuren and Ooms 2009). The resulting scores can be
plotted against age to produce the stage line diagram. A
first stage, like B1 (breasts-1, meaning no sign of growth
yet) is present in 100% (mid p value) of the general
population of 8-year-old girls, but in 12-year-old girls, this
stage occurs only in 10% of the girls (late), SDS=1,645.
For the most mature breasts stage, B5, the opposite is true;
for 13-year-olds, this stage occurs only in 10% of the girls
(early), whereas the mid-p value of 100% is reached in
nearly all 20-year-olds.
Results
Demographics and melatonin use
The questionnaire was returned by 59 of the 69 children
(Fig. 1). Two children continued melatonin use for less than
6 months, and refrained from completing the questionnaire.
The mean age of the remaining 57 children was 12.0 (min
8.6, max 15.7 years). Nine children discontinued melatonin
therapy after more than 6 months and did complete the
questionnaire. Melatonin was still used by 48 children at
the time of questioning, mean duration of use was 3.1 years
(min 1.0, max 4.6 years) and mean dose was 2.7 mg (min
0.3, max 10 mg) (Table 1).
Effect of cessation
Eleven children stopped therapy. In one case because the
family physician decided that 6 months of therapy was
enough, one boy because even 10 mg of melatonin did not
have a sustained effect, one girl because of the adverse
event of apathy combined with weight gain, and eight
children because the need of early sleep disappeared. Of
those eight, one child indicated to have adopted a delayed
sleeping pattern and one child accepted increased sleep
onset latency. The remaining six children indicated the
sleep onset insomnia had disappeared.
Drug-free intervals
Melatonin therapy was interrupted during holidays by 31
children. Reasons for interruption were the advice of the
prescribing physician, a delayed rhythm during holidays
and checking the continuing need for melatonin to advance
sleep rhythm. Four children skip (ped) medication on a
regular basis every week, for instance in the weekends, or 1
or 3 days a week. Eighteen children never skip (ped)
medication (unless forgotten).
Adverse events
Several adverse events were reported: nausea at start (one
child), apathy combined with weight gain (one child),
weight gain (one child), nocturnal diuresis (three children),
short temper during high-dose therapy (10 mg) (one child).
We explicitly asked for the occurrence of headache.
Twenty one (38%) children reported suffering from
headache regularly (once a week–once a month), 11
(20%) seldom and 23 (42%) never experienced headache.
Mental health
Mean SDQ score was 9.75 (min 2, max 29, SD=5.72). This
score and the sub-scores of age-related subgroups were
compared with the one sample t test with previously
published scores in controls (Muris et al. 2004; Havas et al.
2010). Muris et al. (2004) studied the validity of the self-
report SDQ in 1,111 Dutch, non clinical children, mean age
10.6years,Havasetal.(2010) studiedmentalhealthproblems
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(33.3%) of this study population were 13 years or above.
We compared the subgroup of children <13 years with the
primary school controls (Muris et al. 2004)a n d≥13 y with
the adolescent controls (Havas et al. 2010). No significant
differences on SDQ (sub) scores were found (Table 2).
Muris et al. (2004) reported boys and girls scores
separately. The conduct problem score of the girls subgroup
aged 8–13 in the Meldos population is statistically signifi-
cantly lower than the primary school controls, as is their
SDQ total score. Other subscores of the girls and all (sub)
scores of the boys did not deviate from controls (Table 3).
Sleep habits
The CSHQ score of our study population was 42.9 (min 34,
max 62) (Table 4). This score and the subscores were
compared with previously published Dutch population
scores (van Litsenburg et al. 2010)( T a b l e4). Two
subscores—sleep onset delay and daytime sleepiness—and
the CSHQ total score were significantly higher than in the
controls, indicative for worse sleep. Sleep-disordered
breathing was significantly lower. In the general population
a subpopulation of problem sleepers (PS) was defined
based on (subjective) parental report endorsing at least one
Assessed for eligibility (n=69)
Included (n=59)
Non responsive (n=10) Enrollment
Analysed (n=56) Analysed (n=57)
Available for analysis
(n=59)
Usage <6 months (n=2)
Skipped questions (n=12)
Demographic and melatonin
usage inventory
24 questions
Available for analysis
(n=59)
Skipped questions (n=0)
Available for analysis
(n=59)
Usage <6 months (n=2)
Skipped questions (n=0)
Available for analysis
(n=59)
Usage <6 months (n=2)
Skipped questions (n=1)
Analysis
Mental health
development SDQ
25questions
Puberty development
Tanner score
3 items + 2 (girls) or 1
additional question(s)
Sleep quality
CSHQ
45 questions
Questionnaires
Analysed (n=59) Analysed (n=45)
Fig. 1 Justification of obtained outcome data
No. Mean SD Min Max Median
Age (year) 57 12.0 1.73 8.6 15.7 12.0
Dose (mg) 54 2.7 1.74 0.3 10.0 2.5
Period of use (year) 51 3.11 0.87 1.00 4.61 3.11
TOA-bedtime interval (h) 56 1.05 0.61 0 2.50 1.00
Sports (h/week) 56 3.80 2.18 0 10 3
Reading (h/week) 55 4.4 3.74 0 15 3
Gaming and watching tv (h/week) 53 13.3 8.34 0 35 14
BMI (kg/m
2) 49 17.8 2.19 13.6 24.6 18.0
Bedtime (hh:mm) 57 20:56 0:44 19:30 22:30 21:00
Sleep time (h/night) 55 9.6 0.85 8 11 10
Table 1 Demographic charac-
teristics of participants
Psychopharmacology (2011) 216:111–120 115of the CSHQ items as a problem (van Litsenburg et al.
2010). In comparison with these PS (23%) in the general
population, the participants of this study had significantly
deviant scores on all eight subscores (indicating better
sleep). When compared to the 77% non-problem sleepers
(NPS) of this study showed, in addition to the three deviant
subscores mentioned earlier, higher subscores for sleep
duration, sleep anxiety and night wakings. In conclusion,
five out of eight subscores indicated statistically significant
worse sleep in this group in comparison with the NPS in the
controls; one score indicated better sleep (Table 4).
In accordance with findings in controls, girls in general
have higher scores than boys. In contrast to that, in this
study population, boys' scores for sleep onset delay were
significantly higher in comparison with controls (1.62 vs
1.25, t value=2.08), and even higher than the girls' scores
(1.53, general population 1.34. t value=1.26, NS).
The questionnaire was developed for parental report on
sleep behaviour of children between 4 and 10 years old. For
this reason, we compared the subgroup of children
<11 years with the controls. In this group of 17 children,
8–10 years old, no significant diversion of CSHQ scores
from the controls was detected (Table 5). The complimen-
tary group of children between 11 and 15 years old showed
three statistically significant higher subscores and the total
score that differed significantly with the age-related
controls, indicating worse sleep.
Pubertal development
Tanner Stages standard deviation scores could be deter-
mined for 16 boys and 30 girls. Female breasts/pubic hair/
menarche SDS were 0.003 (min −1.9, max +1.5)/0.013
(min −1.0, max +1.4)/0.143 (min −.87 max +2.47) (Fig. 2.
for all individual female scores). Male genital development/
pubic hair/testis volume SDS were 0.038 (min −2.1, max
+2.8)/0.171 (min −1.8, max +2.55)/0.299 (min −1.83, max
2.67) (Fig. 3. for all individual male scores). Two boys had
all three SDS outside the 80% percentile: one boy in the 1–
5 percentile early development, one boy in the 5–10
percentile late development.
Comparison of maternal menarche (median 13 years)
with the menarche of the girls (median 12 years) revealed
an earlier menarche, in accordance with Mul et al. (2001)
who reported a 0.25-year reduction of menarche in the
period between 1965 and 1997 in Dutch girls. Oigarche
data in the population of this study and in the general
population are too scarce to draw conclusions.
Table 2 Mental health development in comparison with Dutch primary school children and with Dutch adolescents
This study boys and
girls aged 8–12 (37)
Muris boys and girls
aged 8–13 (1,111)
This study boys and
girls aged 13–15 (19)
Havas boys and girls
aged 13–14 (1,741–1,845)
Mean SD Mean SD t value Mean SD Mean SD t value
SDQ_tot 10.05 6.05 10.4 5.4 −0.35 9.16 5.10 8.28 4.89 0.75
Emotional 2.68 2.20 2.6 2.1 0.21 2.37 2.22 2.09 1.97 0.55
Conduct 1.86 1.78 2.2 1.6 −1.14 1.16 1.21 1.45 1.34 −1.05
Hyperactivity 3.81 3.00 3.7 2.3 0.22 3.53 2.39 3.70 2.45 −0.32
Peer 1.65 1.80 2.0 1.7 −1.19 2.11 2.23 1.07 1.31 2.02
Prosocial 7.38 2.06 7.4 1.7 −0.06 7.89 1.59 8.00 1.65 −0.29
Means of two age subpopulations of this study compared with mean of Muris et al. (2004) and mean of Havas et al. (2010)
Table 3 Mental health development of boys and girls in comparison with a Dutch primary school population
This study boys
aged 8–13 (22)
Muris boys aged 8–13 (549) This study girls
aged 8–13 (25)
Muris girls aged 8–13 (558)
Mean SD Mean SD t value Mean SD Mean SD t value
SDQ_tot 12.05 6.87 10.2 5.3 1.26 8.20 4.58 10.7 5.5 −2.73*
Emotional 2.82 1.97 2.2 1.9 1.47 2.40 2.38 3.1 2.2 −1.47
Conduct 2.09 2.04 2.3 1.7 −0.48 1.40 1.38 2.0 1.5 −2.17*
Hyperactivity 4.64 3.20 3.7 2.3 1.37 2.88 2.33 3.6 2.3 −1.54
Peer 2.41 2.32 2.0 1.7 0.83 1.52 1.58 2.0 1.7 −1.87
Prosocial 7.22 2.26 7.0 1.8 0.47 7.92 1.68 7.7 1.6 0.65
*<0.05 comparing the mean of an age-related subgroup of boys and girls in this study to the mean of boys and girls of Muris et al. (2004)
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Six of the 11 children that stopped therapy indicated that the
delayed sleep onset had disappeared. This suggests that
successful cessation of therapy is attainable after a longer
period of melatonin usage without rebound phenomena as
demonstrated by typical hypnotics. Adverse events occurred
infrequently and were acceptable in most cases, leading to
cessation of melatonin use in 1.6%. Upon explicit inquiry,
though, most children (58%) reported headache. The finding
of regular headaches in 38% of the children was disturbing at
first glance. However, recently, Arruda et al. (2010)r e p o r t e d
a prevalence of low-frequency episodic headaches (suffering
from headaches in the past year but less than 5 days of
headache in the past month) of 38.9% in preadolescent
children from the general population.
The social development of the 57 former participants of
Meldos as measured by SDQ did not deviate from the
children without sleep problems of the general population
(controls), thanks to or in spite of long-term melatonin use.
The sleep habit questionnaire indicated that the sleep
patterns of these long-term melatonin users were not as
good as the sleep patterns of healthy sleepers, but better
than the patterns of 23% of the controls that were
categorized as PS. In fact, all melatonin users were still
satisfied with the results of the therapy.
The CSHQ was recently validated in Dutch children
(Waumans et al. 2010). It was concluded that this
questionnaire is appropriate for ages 4–10, but not for
older children. This outcome might reduce our results to 17
valid scores that, however, did not deviate from the
controls.
Table 4 Sleep habit results compared with problem sleepers and non problem sleepers in a Dutch primary school population
This study total (57) Van Litsenburg
total (1,282–1,507)
Van Litsenburg PS (44–265) Van Litsenburg NPS (888–1,424)
Mean SD Mean t value Mean t value Mean t value
Bedtime resistance 6.79 1.54 6.68 0.535 8.81 −9.88*** 6.54 1.22
Sleep onset delay 1.57 .83 1.30 2.45* 2.11 −4.87*** 1.25 2.90**
Sleep duration 3.79 1.35 3.50 1.62 4.88 −6.12*** 3.42 2.07*
Sleep anxiety 5.18 1.64 4.86 1.45 7.07 −8.73*** 4.70 2.19*
Night wakings 3.86 1.08 3.62 1.68 5.74 −13.19*** 3.55 2.17*
Parasomnias 8.33 1.65 8.57 −1.08 10.85 −11.51*** 8.40 −0.30
Sleep-disordered breathing 3.12 0.54 3.30 −2.49* 5.08 −27.52*** 3.28 −2.21*
Daytime sleepiness 12.53 3.24 11.16 3.19** 13.77 −2.90** 10.94 3.70***
CSHQ_total score 42.91 5.94 40.50 3.06** 44.72 −2.30* 39.25 4.65***
*<0.05, **<0.01, ***<0.001 comparing mean of this study to mean of all, mean of Problem Sleepers (PS) and mean of Non Problem Sleepers
(NPS) of Van Litsenburg et al. (2010)
Table 5 Sleep habit results of two age subgroups compared with a Dutch primary school population
This study 7–10 (17) Van Litsenburg
7–10 (554–632)
t-value This study 11–15 (40) Van Litsenburg
10–14 (412–507)
t value
Mean Mean Mean Mean
Bedtime resistance 6.76 6.74 0.093 6.80 6.48 1.22
Sleep onset delay 1.59 1.29 1.41 1.56 1.43 1.02
Sleep duration 3.29 3.49 −1.18 4.00 3.57 1.81
Sleep anxiety 5.35 4.96 0.98 5.10 4.56 2.08*
Night wakings 3.47 3.59 −0.56 4.02 3.44 3.30**
Parasomnias 8.24 8.64 −0.83 8.38 8.23 0.61
Sleep-disordered breathing 3.24 3.29 −0.40 3.08 3.24 −1.98
Daytime sleepiness 11.94 11.02 0.93 12.78 11.52 2.82**
CSHQ_total score 41.47 40.57 0.67 43.52 40.16 3.50***
*<0.05, **<0.01, ***<0.001 comparing means of this study to mean of boys, mean of girls, mean of aged 7–10 and mean of aged 10–14 of Van
Litsenburg et al. (2010)
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age of 13 during the follow-up period, which allowed us to
evaluate the effects of melatonin therapy on timing of
puberty development. The Tanner results indicated undis-
turbed puberty onset, as did the comparisons of menarche
of the girls and their mothers. However, only 62% of the
boys and 91% of the girls answered the Tanner score
questions. Fourteen children (three girls and 11 boys) did
not answer this part of the interview. The reluctance to
answer the Tanner questions could be caused by (real or
perceived) deviated pubertal development, but might also
emerge from the strong religious background of some of the
children, as for instance, is demonstrated by the absence of
TV watching or gaming in some of the children
(concerning only boys, not shown) (Table 1). The self-
assessment of the scores instead of an intrusive physical
Fig. 3 Pubertal development; stage line diagram with SDS plot for
boys (n=15). This figure depicts the SDS values for development of
genitals (blue lines, five stages), pubic hair (green lines, five stages)
and testis (red lines, eight volumes) of 15 boys. The black circles
depict the three SDS values for three individual boys, the first circle
represents a boy with an early development, almost p99 values for all
parameters, the middle circle represents a boy with p50 development,
and the third circle represents a boy with late development of all
parameters (p5)
Fig. 2 Pubertal development:
stage line diagram with SDS
plot for girls (n=30). This figure
depicts the SDS values for de-
velopment of breast (blue lines,
five stages), pubic hair (green
lines, five stages) and menarche
(red lines, yes or no) of 30 girls.
The black circles depict the
three SDS values for three indi-
vidual girls, the first circle rep-
resents a girl with an early
menarche and nearly p90 values
for breast and pubic hair, the
middle circle represents a girl
with p50 development, and the
third circle represents a girl with
normal menarche but late breast
development
118 Psychopharmacology (2011) 216:111–120examination by a physician might have augmented the
response rate at the expense of the objectivity of the results.
The phenomenon of repetitive loss of response after
initial good response and dose escalation, in response to the
effect, wearing off was described in three case reports of
(Braam et al. 2010). The loss of response was associated
with CYP1A2 poor metabolism, resulting in the loss of
rhythmicity of melatonin levels due to saturation kinetics.
The incidence of slow CYP1A2 metabolism ranges from
12% to 14% (Butler et al. 1992; Nakajima et al. 1994; Zhou
et al. 2009). The boy in who even 10 mg melatonin failed
might be a slow metaboliser for CYP1A2.
Some other limitations of our study need to be
addressed. The children in our study came from one sleep
clinic, and the sample with long-term results is small, 57
children. This population might not be representative for
otherwise healthy Dutch children with CSOI. A recently
published long-term study (Hoebert et al. 2009) studied the
efficacy and safety in a larger population (99). In this study,
only 8% of the children stopped therapy after 4 years of
treatment. However, most of these children suffered from
other health problems, remained under supervision of a
specialist and used other medication as well.
For evaluation of long-term effects and results of any
intervention, one would ideally apply the same measure-
ments in due course. The Meldos study applied a sleep
hygiene questionnaire that was deemed inappropriate for
the older children of the present evaluation. Even more,
even the applied CSHQ was recently invalidated. So, the
CSHQ scores may only be valid for 17 children.
In conclusion, we found that melatonin was still used
by 81% of children, after a mean term of usage of
3.1 years. Six (10%) children stopped therapy success-
fully, two others adopted a delayed sleep pattern after
cessation. One girl quit melatonin therapy because of
apathy and weight gain, one boy quit because of loss of
response. One girl was forced to stop therapy by her GP
after 6 months. The CSHQ results indicate that the sleep
habits in melatonin users are better than in PS without
medication, but worse than in NPS. Social development
assessed by SDQ indicates a normal development.
Puberty onset, as assessed by Tanner scores, seems to
be undisturbed after 3.1 years of exogenous melatonin
usage in this limited population.
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